We aim for new, innovative solutions to fight multi-drug resistant bacteria. Due to the increasing prevalence of resistance against marketed antibiotics, we address a need which is growing dramatically. A lack in the innovation of antibiotics must not be considered only by itself but would be associated with high co-morbidity by untreatable infections affecting other clinical areas such as oncology, COVID-19 and surgery. For this reason, innovation in the field of antibacterial agents is essential for an overall functioning healthcare system. At the same time, developing a new drug takes many years, so preventing a resistance crisis tomorrow means taking action today.